<p> The FDA recently approved a nasal powder formulation of glucagon that simplifies the process of administering treatment to patients who are experiencing severe hypoglycemia but are not able to treat themselves.</p>

The FDA recently approved a nasal powder formulation of glucagon that simplifies the process of administering treatment to patients who are experiencing severe hypoglycemia but are not able to treat themselves.

Univadis Practice Changers: FDA approves first nasal glucagon for severe hypoglycemia

If you're a family medicine physician or other primary care clinician, you know how hard it is to keep up with the latest research. The Univadis Practice Changers podcast provides expert analysis on the most essential new evidence in medicine. In 5 minutes or less, you'll hear experts go beyond the details of the latest study to the real-world clinical applications. Univadis Practice Changers is a quick look at essential evidence changing your daily practice.

Share Univadis Practice Changers: FDA approves first nasal glucagon for severe hypoglycemia

Sign up to save your podcasts

Univadis Practice Changers: FDA approves first nasal glucagon for severe hypoglycemia

Univadis Practice Changers: FDA approves first nasal glucagon for severe hypoglycemia